PHARMACY & PHARMACOLOGY (PHARM) -> PHARM - Lung Abstracts

1298 - Tailored Immunosuppression Using CYP3A5 Metaboliser Status in Heart and Lung Transplant Cases - An Indian Study

Presentation Number
1298
Speakers
Session Name
POSTER SESSION 3 - POSTER SESSION: Pharmacy and Pharmacology
Date
Fri, Apr 24, 2020
Time
06:00 PM - 07:15 PM
Authors

Previous ePresentation
1297 - Voriconazole Associated Adverse Drug Events and Drug Monitoring in Lung Transplant (LTx) Recipients

Next ePresentations
1300 - Cytomegalovirus Immune Globulin (CMV-Ig): An Old Drug with Fewer Tricks - Removal of Prophylactic CMV-Ig Administration in CMV Mismatched Lung Transplant Recipients
1304 - Correction of Iron Deficiency with Intravenous Iron Replacement Immediately after Left Ventricular Assist Device Implant
1305 - Incidence of Major Bleeding Associated with International Normalized Ratio Greater Than 4.0 in a Cohort of Mechanical Circulatory Support Device Patients
1307 - Tricuspid Surgery and Pulmonary Thromboendarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension
1308 - The Effect of Exercise on Endothelin 1 Level in Patients with Pulmonary Hypertension
1310 - Treatment of Drug- and Toxin-Induced Pulmonary Arterial Hypertension (PAH): Real-World Experience with Macitentan
1313 - Prognostic Significance of Echocardiographic Parameters in Predicting Early Decline in Patients with Pulmonary Arterial Hypertension
1314 - Adding Echocardiography of the Right Heart to Risk Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension
1325 - Cangrelor with Heparin for Patients with Heparin-Induced Thrombocytopenia Undergoing Pulmonary Thromboendarterectomy
1329 - Dobutamine-Induced Eosinophilic Myocarditis in Decompensated Heart Failure: A Paradoxical Dilemma